EGFR and lung adenocarcinoma: Additionally, inhibition of mutant EGFR with the third-generation inhibitor osimertinib in lung adenocarcinoma cells has been shown by one group to cause the up-regulation of the tyrosine kinase receptor AXL [16], and by another group to cause the up-regulation of the mitotic protein kinase AURKA [17].